Drugs / domagrozumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT02907619 | Oct 2016 → Nov 2018 | Duchenne muscular dystrophy | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT02310763 | Nov 2014 → Apr 2018 | Duchenne muscular dystrophy | Pfizer | Terminated | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01616277 Comparator | Jun 2012 → Aug 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT02841267 Comparator | Jul 2016 → Jan 2019 | autosomal recessive limb-girdle muscular dystrophy type 2I | Kathryn Wagner | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-08-30 | Pfizer | Results Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy pfizer.com ↗
Further evaluation of the totality of evidence including secondary endpoints did not support a significant treatment effect. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-30 | Pfizer | Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | domagrozumab | “Domagrozumab, a humanized recombinant monoclonal antibody, binds myostatin and inhibits activity.” PMID 36104012 ↗ Oct 2022 |
| Known as | PF-06252616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01616277 ↗ |
| Action | Inhibit | “Growth/differentiation factor 8 inhibitor” CHEMBL3544991 ↗1“binds myostatin and inhibits activity” PMID 36104012 ↗ Oct 2022 |
| Modality | Monoclonal antibody | “a humanized recombinant monoclonal antibody” PMID 36104012 ↗ Oct 2022 |
| Route | Intravenous | “1.0 milligram per kilogram of PF-06252616, IV infusion, single dose” NCT01616277 ↗ |
| Target | MSTN | “Growth/differentiation factor 8 inhibitor” CHEMBL3544991 ↗ |